for its lead product candidate BMF-219, and that the United States Adopted Name Council has adopted “icovamenib” as the United States Adopted Name (USAN) for BMF-219. The suffix ‘-menib ...
Biomea Fusion (BMEA) announced that the World Health Organization, WHO, has approved “icovamenib” as the International Nonproprietary Name, INN, for its lead product candidate BMF-219 ...
GlobalData on MSN1mon
Biomea’s stock bounces back as FDA lifts clinical hold on diabetes trialsBiomea Fusion’s stock is on the up after the company plans to resume two clinical trials evaluating its therapy for type 1 ...
Two trial-in-progress oral presentations to feature Phase II study design of oral covalent menin inhibitor BMF-219 in patients with type 2 diabetes (COVALENT-111) and in patients with type 1 ...
for its lead product candidate BMF-219, and that the United States Adopted Name Council has adopted “icovamenib” as the United States Adopted Name (USAN) for BMF-219. The suffix ‘-menib ...
Any such statements in this press release that are not statements of historical fact, including statements regarding the clinical and therapeutic potential of our product candidates and development ...
Any such statements in this press release that are not statements of historical fact, including statements regarding the clinical and therapeutic potential of our product candidates and development ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback